DaVita Inc. (DVA)
NYSE: DVA · Real-Time Price · USD
117.27
-4.28 (-3.52%)
Nov 17, 2025, 4:00 PM EST - Market closed
DaVita Employees
DaVita had 76,000 employees as of December 31, 2024. The number of employees increased by 6,000 or 8.57% compared to the previous year.
Employees
76,000
Change (1Y)
6,000
Growth (1Y)
8.57%
Revenue / Employee
$175,236
Profits / Employee
$10,157
Market Cap
8.28B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 76,000 | 6,000 | 8.57% |
| Dec 31, 2023 | 70,000 | 0 | - |
| Dec 31, 2022 | 70,000 | 1,000 | 1.45% |
| Dec 31, 2021 | 69,000 | 2,000 | 2.99% |
| Dec 31, 2020 | 67,000 | 2,000 | 3.08% |
| Dec 31, 2019 | 65,000 | -12,700 | -16.34% |
| Dec 31, 2018 | 77,700 | 3,200 | 4.30% |
| Dec 31, 2017 | 74,500 | 4,200 | 5.97% |
| Dec 31, 2016 | 70,300 | 9,900 | 16.39% |
| Dec 31, 2015 | 60,400 | 2,500 | 4.32% |
| Dec 31, 2014 | 57,900 | 500 | 0.87% |
| Dec 31, 2013 | 57,400 | 4,000 | 7.49% |
| Dec 31, 2012 | 53,400 | 12,400 | 30.24% |
| Dec 31, 2011 | 41,000 | 4,500 | 12.33% |
| Dec 31, 2010 | 36,500 | 2,500 | 7.35% |
| Dec 31, 2009 | 34,000 | 1,500 | 4.62% |
| Dec 31, 2008 | 32,500 | 1,500 | 4.84% |
| Dec 31, 2007 | 31,000 | 2,100 | 7.27% |
| Dec 31, 2006 | 28,900 | 900 | 3.21% |
| Dec 31, 2005 | 28,000 | 12,700 | 83.01% |
| Dec 31, 2004 | 15,300 | 1,500 | 10.87% |
| Dec 31, 2003 | 13,800 | 800 | 6.15% |
| Dec 31, 2002 | 13,000 | 300 | 2.36% |
| Dec 31, 2001 | 12,700 | 500 | 4.10% |
| Dec 31, 2000 | 12,200 | -100 | -0.81% |
| Dec 31, 1999 | 12,300 | 0 | - |
| Dec 31, 1998 | 12,300 | 3,470 | 39.30% |
| Dec 31, 1997 | 8,830 | 5,705 | 182.56% |
| Dec 31, 1996 | 3,125 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DVA News
- 15 hours ago - DaVita Inc. (DVA) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript - Seeking Alpha
- 3 days ago - DaVita Inc. to Participate in Fireside Chat with Wolfe Research - PRNewsWire
- 13 days ago - DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025 - PRNewsWire
- 19 days ago - DaVita Inc. (DVA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - DaVita misses quarterly profit estimates on rising costs, lower volumes - Reuters
- 19 days ago - DaVita Inc. 3rd Quarter 2025 Results - PRNewsWire
- 4 weeks ago - DaVita Leads the Way in Evaluating Middle Molecule Clearance with Two New Initiatives - PRNewsWire
- 5 weeks ago - DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call - PRNewsWire